Benzinga · Feb 18, 2026
AL
NASDAQ · ALLR
Allarity Therapeutics, Inc.
Healthcare · Biotechnology
$1.13
Up+$0.15 (+15.58%)
Updated Nov 4, 2026, 2:07 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 15.6M
- P/E ratio
- -0.93
- Dividend yield
- 0.00%
- 52-week range
- $0.80 – $1.84
- Volume
- 323.16K
- Avg. volume
- 162.56K
Price performance · ALLR
ALLR price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
ALLR closed at $1.13 after 21 trading sessions, up 14.69% for the selected period.
- Last close
- $1.13
- Period change
- +14.69%
- Period low
- $0.83
- Period high
- $1.13
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $0.9801 | $1.13 | $0.98 | $1.13 | 323.16K |
| Nov 2, 2026 | $0.8735 | $1.03 | $0.8735 | $0.9777 | 166.85K |
| Oct 30, 2026 | $0.89 | $0.9046 | $0.85 | $0.8704 | 179.45K |
| Oct 29, 2026 | $0.915 | $0.938 | $0.854 | $0.89 | 150.07K |
| Oct 28, 2026 | $0.93 | $0.9594 | $0.91 | $0.95 | 71.19K |
| Oct 27, 2026 | $0.93 | $0.96 | $0.90 | $0.92 | 136.06K |
| Oct 26, 2026 | $0.8727 | $0.9575 | $0.87 | $0.9151 | 174.22K |
| Oct 23, 2026 | $0.8421 | $0.8963 | $0.84 | $0.8654 | 71.07K |
| Oct 22, 2026 | $0.8799 | $0.8799 | $0.8246 | $0.8466 | 90.85K |
| Oct 21, 2026 | $0.8732 | $0.9023 | $0.84 | $0.8796 | 88.75K |
| Oct 20, 2026 | $0.8899 | $0.9075 | $0.8701 | $0.8758 | 108.54K |
| Oct 19, 2026 | $0.8983 | $0.9149 | $0.821 | $0.873 | 86.95K |
| Oct 16, 2026 | $0.871 | $0.92 | $0.821 | $0.895 | 232.06K |
| Oct 15, 2026 | $0.8974 | $0.8999 | $0.80 | $0.8327 | 323.18K |
| Oct 14, 2026 | $0.8824 | $0.8899 | $0.86 | $0.8733 | 64.08K |
| Oct 13, 2026 | $0.88 | $0.91 | $0.8303 | $0.8699 | 111.49K |
| Oct 12, 2026 | $0.97 | $0.99 | $0.8319 | $0.8601 | 416.39K |
| Oct 9, 2026 | $0.995 | $1.04 | $0.99 | $0.99 | 97.23K |
| Oct 8, 2026 | $0.995 | $1.00 | $0.95 | $0.9819 | 63.78K |
| Oct 7, 2026 | $1.02 | $1.04 | $0.981 | $0.984 | 81.04K |
| Oct 6, 2026 | $0.9826 | $0.9999 | $0.98 | $0.9853 | 46.34K |
Latest ALLR news
The latest Smart Investors Daily articles mentioning ALLR.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ALLR research
Overview
Company profile and research snapshot.
Company profile
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $9.44
- Implied upside
- —
- Analysts
- 7
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | Ascendiant Capital | Buy | — |
| Jun 8, 2026 | Ascendiant Capital | Buy | — |
| Apr 10, 2026 | Ascendiant Capital | Buy | — |
| Dec 9, 2025 | Ascendiant Capital | Buy | — |
| Sep 26, 2025 | Ascendiant Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 18, 2026
Allarity Therapeutics Doses the First Patients With Stenoparib And Temozolomide In VA-Funded Investigator-Initiated Phase 2 Trial For Relapsed Small Cell Lung Cancer
Benzinga · Feb 12, 2026
Allarity Therapeutics Files Prospectus For Offering 255K Common Shares By Selling Stockholder
SEC.
Benzinga · Feb 3, 2026
Allarity Therapeutics Starts Enrollment For Phase 2 Trial To Developing Senoparib
This is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's favorable safety profile supports potential for use in combination regimens Trial is fully funded by the U.S.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
